Articles tagged with Alzheimer Disease
A novel method has been developed to examine protein structure and function at the cell level using formalin-fixed paraffin-embedded (FFPE) tissue. This allows for precise study of protein changes in Alzheimer's disease, a neurodegenerative condition.
Researchers at Columbia University Irving Medical Center analyzed data from 8,846 individuals over 50 years old with celiac disease, finding no increased risk of dementia before or after diagnosis. However, a small increase in vascular dementia was observed in patients with celiac disease.
A blood test that detects Alzheimer's disease presence has shown promise in early detection, allowing patients to make beneficial lifestyle changes to slow or halt disease progression. This discovery provides hope for those affected by the disease, enabling them to take proactive steps before symptoms emerge.
Researchers have identified GPR3 as a potential therapeutic target for Alzheimer's disease, finding that its absence alleviates cognitive decline and reduces amyloid pathology in multiple models. The study provides preclinical validation for GPR3, setting the stage for future AD drug development.
A study found that antipsychotic drugs are initiated in Alzheimer's patients 2-3 years before diagnosis and used for over a year. This contradicts current treatment guidelines, increasing the risk of adverse incidents like stroke and death.
A recent IRB Barcelona study has questioned the widely accepted premise about the number of molecules and shape of amyloid beta protein's initial aggregates. The research found that Abeta 40 and Abeta 42 form the same aggregation states, contradicting previous findings, which used a technique that may be biased.
A team of researchers at Charité - Universitätsmedizin Berlin found that peripheral macrophages can be repurposed to clean up beta-amyloid deposits in the brain. However, even with stimulation, these cells were ineffective and require further investigation into a missing stimulus.
Researchers at MIT are developing a computer system that uses genetic, demographic, and clinical data to predict the effects of neurodegenerative disease on brain anatomy. By combining MRI data with additional patient information, they found that predictions were improved by half in cases where changes were drastic.
Microglia facilitate the spread of tau fibrils between neurons by releasing exosomes, which could lead to a novel therapeutic target for Alzheimer's disease. Pharmacologic depletion and inhibition of exosome production suppress tau spread, restoring neural excitation.
Researchers found similarities between horse sickness and human conditions like Alzheimer's disease in a study published in Molecular and Cellular Proteomics. The findings shed light on the causes of equine grass sickness, a rare but fatal condition that can be tricky to diagnose.
A new study found a variant in the IL1RAP gene associated with higher rates of amyloid plaque accumulation and cognitive decline in Alzheimer's patients. The research suggests targeting the IL1RAP immune pathway may be a viable approach for clearing amyloid deposits and fighting disease progression.
Katie Maslow, MSW, of the Institute of Medicine, has been chosen as the 2015 recipient of the Maxwell A. Pollack Award for Productive Aging. She will receive the award for her innovative programs that demonstrate excellence in translating research into practical application or policy.
A University of Texas at Arlington professor will analyze complex data using imaging genomics to identify biomarkers predicting Alzheimer's disease risk. He aims to develop advanced algorithms to study the brain, incorporating biological knowledge into data sets.
The National Institute on Aging has awarded a grant of $3.567M to study mechanisms of Alzheimer's disease, with a focus on immune system cells that cause synapse damage.
The Collaboration for Alzheimer's Prevention (CAP) brings together researchers from six clinical trials to share information, resources, and expertise. CAP aims to accelerate the evaluation of preclinical Alzheimer disease treatments through data harmonization and standardization.
Researchers at Brigham and Women's Hospital have found a link between genetic risk factors for Alzheimer's disease and key immune cells, paving the way for new diagnostic tools and treatments. The study suggests that higher levels of TREM2 may be associated with increased risk of Alzheimer's disease.
Researchers designed molecules that suppress protein aggregation, a process damaging cells in Alzheimer's and type 2 diabetes. The findings reveal a novel class of peptide leads that could pave the way for new treatments.
A new Lund University study found that both amyloid PET imaging and cerebrospinal fluid samples are effective methods for detecting early-stage Alzheimer's disease. The two methods identified approximately 90% of patients with the disease, making them equally viable options.
A recent University of Eastern Finland study found that spousal and family caregivers experiencing depressive symptoms after an Alzheimer's diagnosis experience greater psychological stress. The study suggests it is essential to consider the caregiver's mental health at diagnosis time for providing adequate support.
Researchers repurposed salsalate to reverse tau-related dysfunction in an animal model of frontotemporal dementia, effectively lowering tau levels and rescuing memory impairments.
Scientists at Trinity College Dublin have discovered a fundamental mechanism underlying Alzheimer's disease, which could lead to new forms of therapy. The research, published in Science Advances, highlights the importance of understanding diseases at the molecular level and finding ways to remove toxic amyloid-beta from the brain.
A recent study by Dr. Sylvie Belleville and her team has identified typical patterns of brain progression towards Alzheimer's disease, revealing a complex path characterized by periods of stability followed by accelerated decline. The study suggests that rapid memory decline is a key indicator of risk, allowing for earlier treatment.
A study published in Frontiers in Behavioral Neuroscience has confirmed the pathogenic role of beta amyloid in dementia, both in Down syndrome and Alzheimer's disease. Researchers found that people with Down syndrome develop abnormal protein at twice the rate, providing insights into how Alzheimer's naturally progresses.
Researchers found a stress-coping hormone releases a protein fragment called amyloid beta, which clumps together and leads to Alzheimer's disease. The study strengthens the idea of a link between stress and Alzheimer's, providing insight into potential treatment approaches.
A new UCLA study reveals that Alzheimer's disease consists of three distinct subtypes, each requiring targeted research and potential new treatments. The cortical subtype appears to be fundamentally different from the other two, suggesting different causes and optimal treatment approaches.
Researchers discovered that a stress-coping hormone boosts amyloid beta production, leading to brain degeneration and Alzheimer's disease. The study strengthens the idea of a link between stress and Alzheimer's disease.
A new study could lead to a single drug that treats both diseases. The research focuses on the link between Abeta peptides and type 2 diabetes, offering hope for therapeutic advances.
Researchers discovered a potential mechanism for neurodegenerative diseases, suggesting that HSD10 reduces oxidative stress and promotes cell repair in humans. This breakthrough provides a fresh perspective on Alzheimer's disease etiology and could inform novel drug strategies.
Researchers at RIKEN Brain Science Institute developed a new optical clearing technique called Sca l eS, enabling the creation of transparent brain samples for detailed analysis. The technique has provided new insights into Alzheimer's disease pathology and revealed associations between amyloid beta plaques and microglial cells.
BACE1 and APH1B-y-secretase control axonal guidance by regulating growth cone collapse and restoration. Inhibition of these proteases may have physiologically opposite effects, suggesting cautious combination therapies to mitigate side effects.
A new study reveals a direct relationship between Alzheimer's disease and brain cholesterol levels. Increasing the enzyme CYP46A1 may help eliminate excess cholesterol from the brain, correcting amyloid plaques and degenerated tau protein. This discovery opens up a new line of research for Alzheimer's treatment.
A study of nearly 400 participants aged 76+ found that low vitamin D levels accelerate cognitive decline and increase dementia risk. Individuals with dark skin or insufficiency were disproportionately affected.
Researchers found that high-dose resveratrol stabilized a biomarker associated with Alzheimer's disease progression. The study, involving 119 participants, also showed that resveratrol was safe and well-tolerated, but its effects on brain volume were unclear.
A new Michigan State University study aims to identify early signs of Alzheimer's disease among Latinos and Hispanics, potentially delaying or preventing its onset. The $5.67 million grant will gather health data from nearly 7,000 middle-aged and older adults, with the goal of differentiating mild cognitive impairment from normal aging.
Researchers found that human umbilical cord blood-derived monocytes improved hippocampal-dependent learning, memory, and motor function in AD modeled mice. The study suggests that these cells may exert therapeutic effects through phagocytosis of dead cells and cellular debris.
A team of researchers at the University of Kansas has identified a potential neuroprotective mechanism for Alzheimer's disease, focusing on the ApoE2 gene. The study suggests that ApoE2 carriers may be resistant to Alzheimer's disease due to enhanced brain energy metabolism.
A panel of world experts recommends annual brain health screenings for individuals 70 and older, citing high rates of memory problems among this age group. Lifestyle changes, such as a Mediterranean-type diet, exercise, and intellectual activities, can slow cognitive decline.
A gene signature associated with 'healthy ageing' has been identified, allowing for early prediction of age-related diseases like Alzheimer's. The discovery provides a reliable molecular profile for distinguishing people at risk and could transform medical decision-making.
A recent study published in Neuron highlights a novel role for the appoptosin protein in initiating tau aggregation, a key component of brain lesions. Elevated levels of appoptosin increase caspase-mediated tau cleavage, leading to synaptic dysfunction and progressive deterioration of the central nervous system.
A new study found that people with type 2 diabetes have double the risk of developing dementia and exhibit higher levels of tau protein in the spinal fluid. Diabetes was also associated with reduced cortical thickness, suggesting a potential link to brain cell death.
A specific group of genes controls calcium ion concentration, crucial for memory performance and Alzheimer's development. The study provides new insights into the origins of the neurodegenerative disorder.
Scientists have identified a gene variant that slows Alzheimer's disease progression by preventing eotaxin levels from increasing with age. The study found that individuals carrying this variant experienced a modest delay in disease onset, suggesting a potential protective mechanism against the disease.
Researchers have identified a new protein fragment, amyloid-η, which antagonizes the hyperactive effect of beta-amyloid on nerve cells. This finding has immediate implications for ongoing clinical trials targeting beta-amyloid, suggesting that unanticipated side-effects may occur if eta-amyloid levels increase
Researchers have discovered accumulations of fat droplets in the brains of patients with Alzheimer's disease and found that these abnormal fat deposits could be a trigger for the disease. The study suggests that treating fatty acid production may help prevent or delay the progression of Alzheimer's disease.
Researchers found that degenerating neurons in patients with Alzheimer's disease responded to gene therapy treatment by showing heightened growth, axonal sprouting, and activation of functional markers. The study suggests that nerve growth factor is safe over extended periods and merits continued testing as a potential AD treatment.
The Harrington Discovery Institute has selected scholars to collaborate with R&D partners, including University of Oxford, Alzheimer's Drug Discovery Foundation and Foundation Fighting Blindness. The program aims to bridge the 'Valley of Death' gap in bringing new medications from lab to market.
Researchers have identified a key feature of the Alzheimer's disease-causing Amyloid beta molecule using laser light and fat-coated silver nanoparticles. The study suggests that designing a drug molecule to attack this specific shape could lead to a breakthrough in Alzheimer's treatment.
A large NIH clinical trial of 4,000 patients found that omega-3 supplements had no effect on cognitive decline. Researchers tested the combination of omega-3 fatty acids and lutein/zeaxanthin, but saw no benefit in slowing age-related macular degeneration (AMD) or dementia.
Researchers at Rockefeller University identified a molecular pathway that can dampen amyloid-β production, a hallmark of Alzheimer's disease. By targeting this pathway, it may be possible to develop drugs to reduce amyloid-β and potentially treat or prevent the disease.
Studies show that changes in moral behavior, not memory loss, cause loved ones to say the patient isn't 'the same person' anymore. Moral faculties form core of individual identity perception, according to researchers.
Researchers altered a gene in mice to inhibit PDE4B, leading to enhanced cognitive abilities and reduced anxiety. The findings offer hope for better treatments for age-related cognitive decline, Alzheimer's disease, and schizophrenia.
Researchers found that people over 80 years old take over 10 hours to clear amyloid beta 42 from the brain, leading to rising levels and increased Alzheimer's disease risk. The study suggests age-related changes in brain clearance may drive the disease.
A recent study found that older adults who followed the MIND diet more rigorously showed equivalent cognitive abilities to those 7.5 years younger, suggesting a potential delay of dementia's onset. The MIND diet emphasizes brain-healthy food groups and limits unhealthy foods, with berries being a key component.
African-American participants showed a significant decline in dementia incidence rates from 1992 to 2011 compared to a stable rate among Yoruba individuals in Nigeria. The study suggests that medication for cardiovascular conditions may contribute to the decline.
Researchers discovered insulin delivered via nasal cavity reaches affected brain areas, improving memory in a mouse model. The study suggests potential future treatments using gastrointestinal hormones like insulin to combat Alzheimer's disease.
BrightFocus Foundation has awarded $11 million in research grants to 58 scientists worldwide. The grants focus on treatments for age-related diseases such as Alzheimer's, glaucoma, and macular degeneration, with a emphasis on early detection, disease progression, and potential interventions.
A recent study found that dementia patients and caregivers prefer increased funding for caregiving support and resources over research for an Alzheimer's cure. The majority of respondents ranked financial resources for respite care, long-term care support, and advocacy as top priorities.
A new study reveals that a shorter form of the brain protein beta amyloid can bind to copper safely, potentially offering a protective role against Alzheimer's disease. This discovery challenges the long-held copper hypothesis and may lead to new therapies targeting the condition.
A study published in Radiology found associations between specific cardiovascular risk factors, such as alcohol consumption and smoking, and reduced brain volume in key regions. These findings suggest that risk factors may be early indicators of cognitive decline and Alzheimer's disease.
A new Iowa State University study found a strong association between insulin resistance and memory function decline, increasing the risk for Alzheimer's disease. Insulin resistance is common in people who are obese, pre-diabetic or have Type 2 diabetes, and can lead to cognitive decline at any age.